Month: September 2026

Shanghai, China, Sept. 15, 2026 (GLOBE NEWSWIRE) — Huachen AI Parking Management Technology Holding Co., Ltd. (NASDAQ: HCAI, “Huachen” or the “Company”),  a China‑based provider of equipment structural components and electric vehicle charging solutions and services, today announced that it has entered into securities purchase agreements with certain institutional investors for the purchase and sale of an aggregate of 2,750,000 Class A Ordinary Shares, par value of US$0.0000375 per share, of the Company (the “Ordinary Share”), and Ordinary Warrants to purchase up to 2,750,000 Class A Ordinary Share of the Company (the “Ordinary Warrant”), at a purchase price of $1.00 per Ordinary Share and accompanying Ordinary Warrant. The aggregate gross proceeds from the Offering are expected to be approximately US$2.75 million, prior to deducting placement agent fees, legal fees, administrative and other offering-related expenses.

Each Ordinary Warrant will be immediately exercisable upon issuance at an initial exercise price of US$1.00, which is equal to the offering price per Ordinary Share and accompany Ordinary Warrant. The exercise price of the Ordinary Warrant is subject to customary anti-dilution adjustments in connection with share splits, share combinations, dividend distributions, subsequent equity sale and other corporate restructurings. The Ordinary Warrant will expire on the third anniversary of the issuance date.

The transaction is expected to close on or about September 16, 2026, subject to the satisfaction of customary closing conditions.

Maxim Group LLC is acting as the sole placement agent for the offering. Ortoli Rosenstadt LLP is acting as U.S. securities counsel to the Company, and Pryor Cashman LLP is acting as U.S. securities counsel to the placement agent, in connection with the Offering.

The registered direct offering is being made pursuant to the Company’s registration statement on Form F-3 (File No. 333-296529) previously filed with the U.S. Securities and Exchange Commission (“SEC”), which was declared effective by the SEC on June 12, 2026. A prospectus supplement relating to the securities will be filed by the Company with the SEC. All information filed with the SEC can be obtained over the internet on the SEC’s website located at http://www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, from Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, NY 10022, at (212) 895-3745 or by email at syndicate@maximgrp.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of such securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

About Huachen AI Parking Management Technology Holding Co., Ltd.

Huachen AI Parking Management Technology Holding Co., Ltd. is an exempted company incorporated under the laws of the Cayman Islands. Through its operating subsidiaries in the People’s Republic of China, the Company focuses on the provision of equipment structural components and electric vehicle charging solutions and services.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions, and includes such statements regarding timing of closing, satisfaction of closing conditions, and expected proceeds from the offering. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law.

These forward-looking statements are subject to substantial risks and uncertainties that may cause actual results, performance or achievements to differ materially from those expressed or implied, including without limitation: the Company’s ability to complete the Offering in accordance with the expected timeline and terms; satisfaction of closing conditions; the planned use and actual deployment of net proceeds; adverse changes in global market conditions and capital market sentiment; risks relating to the Company’s business strategy adjustment and asset optimization; the ability to maintain the Company’s Nasdaq listing status; changes in industry policies and regulatory rules; future capital financing needs; and other risk factors disclosed in the Company’s periodic filings and subsequent submissions with the SEC, including its Annual Report on Form 20-F.

Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and in its other filings with the U.S. Securities and Exchange Commission.

Contact

Huachen AI Parking Management Technology Holding Co., Ltd
Alan Li: ir@huachenai.com
Mobile: +852-95791074

Proposed business combination with Fortitude, a vertically-integrated digital asset mining platform anchored in Zcash, continues to progress, with closing expected in Q4 calendar 2026

Commercial effort concentrated on the MyoVista Insights™ platform, with first US commercial agreements signed and selection as the AI-ECG delivery platform for a major European reference center

Southlake, TX, Sept. 15, 2026 (GLOBE NEWSWIRE) — HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today reported financial results for its fiscal first quarter ended July 31, 2026 (“FQ1 2027”) and provided a business update.

Proposed Transaction with Fortitude

The proposed business combination with Fortitude Mining Holdings, Inc. (“Fortitude”), announced in June 2026 (the “Proposed Transaction”), continues to progress. The Company expects to close the Proposed Transaction in Q4 calendar 2026, subject to customary closing conditions, including approval by HeartSciences’ shareholders.

Fortitude is a meaningful part of the Zcash ecosystem and, in our view, Zcash has been among the best-performing large capitalization digital assets over the past year and is attracting growing institutional interest.

Since announcement of the Proposed Transaction, Fortitude has reported a number of developments, including:

• Execution of a purchase agreement for 9,000 Z15 Pro miners, representing approximately 7.5 Gsol/s of Zcash mining capacity;
• Energization of its 12 MW facility in Grand Island, Nebraska; and
• Completion of a 12.5 MW facility in Prosser, Nebraska.

In August 2026, Fortitude subscribed for approximately $1.0 million of shares of HeartSciences’ common stock. The exchange ratio under the merger agreement between Fortitude and the Company was not adjusted as a result, and no additional shares will be issued to Fortitude at closing in respect of the amount invested.

MyoVista Insights

HeartSciences has continued to concentrate its commercial effort on MyoVista Insights, a device-agnostic ECG management and AI orchestration platform that works with the ECG hardware hospitals already own. Progress in the period and since includes:

• First US commercial agreements signed following full launch;
• Availability of the first third-party FDA-cleared AI-ECG algorithm through the AI-ECG algorithm marketplace, with the platform now at version 1.4 following further upgrades since launch;
• Selection of MyoVista Insights as the ECG management and AI-ECG delivery platform for a clinical program at a major European reference center, which is anticipated to extend into a larger multicenter project;
• Launch of a new corporate website built around MyoVista Insights, giving the healthcare industry and its wider stakeholders a much clearer account of the platform’s purpose, functionality, interoperability and benefits, and of how the AI-ECG marketplace is designed to deliver algorithms directly into clinical workflows; and
• Continued expansion of the patent portfolio, including the grant of a European patent for ECG-based assessment of diastolic function, taking the portfolio to more than 45 granted patents.

The Company’s resources continue to be directed primarily to MyoVista Insights. Feedback from clinicians and health systems has been consistently positive, and our priorities are growing revenue, building relationships with key reference centers, and expanding the number of algorithms available through the AI-ECG marketplace.

The FDA 510(k) submission for the MyoVista wavECG device remains under FDA review. However, as previously set out, that submission does not include the AI algorithm necessary for commercialization, which would require significant additional research and development, regulatory and commercialization expenditure over an uncertain timeline and is onerous relative to the software platform. It is also apparent that the emergence of cloud-based AI-ECG algorithms reduces the commercial rationale for a proprietary device with embedded algorithms. These considerations apply irrespective of the outcome of the pending 510(k) review and a probable timeline to commercialization cannot currently be established. Accordingly, the Company has recorded a reserve of $0.3 million against the remaining carrying value of the related inventory and does not currently intend to commit significant additional resources to commercialization of the device.

Management Commentary

“This has been a period of significant change for the Company. The proposed combination with Fortitude is expected to give our shareholders exposure to a business that is a meaningful participant in the Zcash ecosystem. In our view, it represents a significant opportunity for shareholders and the transaction continues to move toward closing,” said Andrew Simpson, CEO of HeartSciences.

Mr. Simpson continued, “We believe MyoVista Insights™ offers a best-in-class, cloud-native, vendor- and device-agnostic ECG management platform designed to modernize ECG workflows and enable scalable deployment of AI-ECG capabilities across healthcare systems. The response from the clinicians using it has been excellent. We have signed our first commercial agreements in the United States, we have been selected as the delivery platform for a clinical program at a leading European reference center, and the AI-ECG marketplace is attracting developers that recognize it as a route to deliver their models directly into clinical workflows at scale. We expect significant commercial progress in the year ahead and our efforts are focused on execution and delivery.”

Fiscal First Quarter 2027 Financial Results

HeartSciences reported no meaningful revenue for FQ1 2027. The loss from operations was $2.9 million (FQ1 2026: $1.9 million), which included an increase of approximately $0.5 million in legal and professional costs associated with the Proposed Transaction, approximately $0.5 million of non-cash share-based compensation arising on the vesting of equity awards following the passing of Mark Hilz, and the $0.3 million inventory reserve referred to above. The net loss for FQ1 2027 was $3.2 million (FQ1 2026: $2.1 million).

As of July 31, 2026, the Company had a shareholders’ deficit of $2.0 million. Since the period end, the Company raised gross proceeds of approximately $1.0 million from a sale of its common stock to Fortitude, raised net proceeds of approximately $1.2 million for sales made pursuant to the Company’s at-the-market facility, and exchanged $200,000 of principal under an existing promissory note for shares of its common stock. The exchange ratio under the merger agreement between Fortitude and the Company was not adjusted as a result of any of these issuances.

Complete financial results are included in the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended July 31, 2026, which was filed with the U.S. Securities and Exchange Commission on September 14, 2026 and is available on the Company’s website at www.heartsciences.com. 

About HeartSciences

HeartSciences is a healthcare information technology company advancing the use of ECG/EKGs through the integration of artificial intelligence. HeartSciences’ MyoVista Insights™ Platform is a cloud-native, vendor- and device-agnostic ECG management system designed to modernize ECG workflows and improve clinical efficiency and decision-making. The platform’s AI-ECG marketplace is designed to deliver AI-ECG algorithms into clinical workflows across a health system’s existing ECG equipment.

For more information, please visit www.heartsciences.com and follow HeartSciences on X @HeartSciences.

About Fortitude

Fortitude, currently wholly-owned by DCG, is an institutional-scale, vertically integrated venture mining platform operating across the Proof-of-Work ecosystem and anchored in Zcash. Fortitude pairs self-mining operations with an owned data center footprint, a diversified power portfolio backed by competitive long-term contracts, and disciplined capital allocation to identify and scale high-conviction opportunities in emerging Proof-of-Work ecosystems, beginning with its leadership position in the Zcash network. Fortitude is led by an experienced team of operators, capital markets professionals, and digital asset specialists with a track record of identifying and scaling high-conviction opportunities and building privacy-preserving digital asset infrastructure.

For more information, visit www.fortitudemining.com and follow Fortitude on X at @FortitudeCrypto.

Cautionary Note Regarding Forward-Looking Information

This press release may contain forward-looking statements concerning HeartSciences, Fortitude and the Proposed Transaction and other matters. These forward-looking statements generally can be identified by the use of words such as “aim,” “anticipate,” “expect,” “plan,” “could,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “potential,” “target,” “objective,” “intend,” and other words of similar meaning, but the absence of these words does not mean that a statement is not forward-looking. All statements HeartSciences and/or Fortitude make in communications that do not relate to matters of historical fact should be considered forward-looking statements.

These forward-looking statements are based on management’s current expectations and assumptions as of the date of such communication and are subject to a number of known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by such statements, which may include, without limitation, the following: the risk that the Proposed Transaction may not be completed on the anticipated timeline or at all; the failure to satisfy the conditions to the closing of the Proposed Transaction, including obtaining the requisite approval of HeartSciences’ shareholders; market, macroeconomic, or other conditions that could adversely affect either HeartSciences or Fortitude, or the combined company; risks related to the integration of the two companies and the management of a newly public company; risks relating to Fortitude’s operations and business, including the highly volatile nature of the price of Zcash and other cryptocurrencies; risks relating to significant legal, commercial, regulatory and technical uncertainty regarding digital assets generally; risks relating to the commercialization of MyoVista Insights, including the rate of adoption by healthcare providers and the conversion of agreements into revenue; and risks relating to the MyoVista wavECG device, including the timing and outcome of the pending FDA 510(k) submission and the recoverability of the related inventory. Additional factors that may cause actual results to differ materially from those expressed or implied by the forward-looking statements in this press release are discussed in HeartSciences’ preliminary proxy statement on Schedule 14A, filed with the SEC on July 27, 2026 in connection with the Proposed Transaction, HeartSciences’ Annual Report on Form 10-K, filed with the SEC on July 23, 2026, HeartSciences’ Quarterly Report on Form 10-Q filed with the SEC on September 14, 2026, and its other reports filed with the SEC from time to time. Readers are cautioned not to place undue reliance on these forward-looking statements. Each of HeartSciences and Fortitude expressly disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law. All forward-looking statements are made as of the date of this press release.

Additional Information About the Proposed Transaction and Where to Find It

This press release may be deemed solicitation material in respect of the Proposed Transaction. In connection with the Proposed Transaction, HeartSciences filed a preliminary proxy statement on Schedule 14A with the SEC on July 27, 2026 and may file additional relevant materials with the SEC. Following the filing of a definitive proxy statement with the SEC, HeartSciences will mail the definitive proxy statement and a proxy card to each shareholder entitled to vote at the special meeting relating to the Proposed Transaction. INVESTORS AND SHAREHOLDERS OF HEARTSCIENCES ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE PROPOSED TRANSACTION THAT HEARTSCIENCES HAS FILED OR MAY FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT HEARTSCIENCES AND THE PROPOSED TRANSACTION. COMMUNICATIONS THAT DO NOT CONTAIN ALL THE INFORMATION THAT SHOULD BE CONSIDERED CONCERNING THE PROPOSED TRANSACTION AND RELATED MATTERS ARE NOT INTENDED TO PROVIDE THE BASIS FOR ANY INVESTMENT DECISION OR ANY OTHER DECISION IN RESPECT OF SUCH MATTERS. The preliminary proxy statement, the definitive proxy statement and other relevant materials in connection with the Proposed Transaction (when they become available), and any other documents filed by HeartSciences with the SEC, may be obtained free of charge at the SEC’s website at www.sec.gov. In addition, investors and shareholders may obtain free copies of the documents filed with the SEC by sending a request to the HeartSciences Investor Relations Department at investorrelations@heartsciences.com.

Participants in the Solicitation

HeartSciences and Fortitude, their respective directors and executive officers, and certain executive officers of Digital Currency Group, Inc., the parent company of Fortitude, may be deemed to be participants in the solicitation of proxies from HeartSciences’ shareholders with respect to the Proposed Transaction. Information regarding the identity of the potential participants, and their direct or indirect interests in the Proposed Transaction, by security holdings or otherwise, is set forth in the preliminary proxy statement and other materials filed or that may be filed with the SEC in connection with the Proposed Transaction.

No Offer or Solicitation

Any information contained herein is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the Proposed Transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. The Proposed Transaction will be implemented solely pursuant to the terms and conditions of the merger agreement, which contain the full terms and conditions of the Proposed Transaction.

Investor Relations and Media Contacts:
HeartSciences
Integrous Communications
Mark Komonoski
Phone: 877-255-8483
Email: mkomonoski@integcom.us

NETANYA, Israel, Sept. 15, 2026 (GLOBE NEWSWIRE) — Tessera Defense and Homeland Security Inc. (NYSE American: HLSQ) (“Tessera” or “the Company”) formerly BiomX Inc (NYSE American: PHGE), today released the following letter from its Chief Executive Officer to shareholders.

Dear Fellow Shareholders,

On September 11 our common stock began trading on the NYSE American under the symbol HLSQ, and our company name was changed to Tessera Defense and Homeland Security Inc. Trading continued without interruption, and no action was required on your part in connection with the name and symbol change. I want to take a moment to explain what this change represents, because a new name and ticker are the visible part of a much larger transformation.

Why now

Governments and organizations are under mounting pressure to protect the systems and sites upon which modern society depends. Recent attacks and suspected acts of sabotage affecting power infrastructure across Europe, incidents involving energy and transportation infrastructure in Germany, and the heightened protection of critical infrastructure across Poland and the Baltic states have placed physical security firmly on the international agenda.

At the same time, the tools available to security teams have not kept pace. Threats routinely cross the boundaries between physical, digital and operational domains, while the systems meant to stop them remain disconnected, each producing its own isolated alert and none producing a picture. That gap is the opportunity we have built the company to address.

What Tessera does

Tessera provides a unified security platform that connects cameras, sensors, detection technologies, artificial intelligence and other security systems into a single intelligent system, and offers solution design and advisory capabilities alongside it. The platform is designed to detect threats, interpret events as they unfold and coordinate response in real time. We are continuing to advance the technical integration of the technologies across our portfolio.

Our capabilities today include the AI-powered security intelligence technology of our subsidiary Zorronet and the LADAR-based detection systems of our subsidiary DFSL, together supporting an integrated approach to advanced sensing, real-time intelligence and autonomous response. We serve customers in homeland security and critical infrastructure and are targeting energy and digital infrastructure, as well as enterprise organizations that need advanced physical security capabilities. These are markets with long procurement cycles, high switching costs and customers who cannot afford to get it wrong, characteristics we believe reward the integrated approach we are building.

We have also published a new investor presentation that provides a more detailed look at Tessera, our platform, our portfolio of technologies, the markets we are targeting and the strategy behind the company we are building. The presentation is available here.

Where we stand

Our second quarter report on Form 10-Q, filed on August 19, was the first to reflect the businesses we acquired in April. Stockholders’ equity attributable to the Company was $10.9 million at June 30, 2026, with total equity of $17.6 million. That is above the continued listing standards of the NYSE American, and includes approximately $25.4 million of goodwill and intangible assets arising from the April acquisitions.

Over the last 3 months we raised over $4 million under our at-the-market (ATM) program at an average price of approximately $2.20 per share on a split-adjusted basis. We effected a one-for-ten reverse stock split on September 9, which adjusted every holder’s position proportionately and reduced our authorized shares from 750 million to 150 million.

The name

A tessera is a single tile that becomes part of a larger mosaic. Our new name reflects both how our platform works and how we are building this company: bringing together complementary technologies across detection, intelligence and response to create one integrated system. No single tile is the picture. The value is in how they fit together.

As threats grow more complex, the people responsible for national security and infrastructure protection need to understand what is happening and act faster and more accurately. Everything we build serves that objective.

The date

The name change took effect on the 25th anniversary of the September 11 attacks. We note the date in remembrance of all those who were lost, including the first responders who gave their lives working to save others.

To our shareholders

Many of you have been with this company through a significant strategic transition. I do not take that lightly. What I can tell you is that the rationale is straightforward: we are directing our resources toward markets where we believe demand is growing and where our technologies are differentiated, with the goal of enhancing shareholder value.

The work ahead is execution: integrating and commercializing our technologies, attracting customers and building the operating discipline our business requires. I look forward to reporting our progress, and I thank you for your continued confidence.

Sincerely,

Michael Oster Chief Executive Officer Tessera Defense and Homeland Security Inc. (NYSE American: HLSQ)

Forward-Looking Statements

This letter contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, platform, capabilities, target markets, the integration of its technologies, its compliance with NYSE American continued listing standards and its financial condition. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties, including risks related to the Company’s ability to execute its strategy, integrate and commercialize its technologies, achieve market acceptance, regain and maintain compliance with NYSE American continued listing standards, and raise additional capital, and those risks described in the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2025, as supplemented by the Form 10-K/A filed on April 30, 2026, and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. Actual results may differ materially from those expressed or implied. The Company undertakes no obligation to update any forward-looking statement, except as required by law.

Investor Contact: Yair Ohayon, IR & Communication Manager, Yairo@thlsq.ai

In accordance with the initiative and decision of the Board of New Energy Group EPSO-G (legal entity code 302826889, registered address Laisvės pr. 10, Vilnius, Lithuania) the Extraordinary General Meeting of EPSO-G shareholders is convened.

Reasons and purposes for calling the meeting: The Board of UAB EPSO-G adopted a resolution to increase the share capital of UAB EPSO-G Invest by EUR 3,360,000, from EUR 7,405,600 to EUR 10,765,600, by issuing 3,360,000 ordinary registered shares of UAB EPSO-G Invest, each with a nominal value of EUR 1; to enter into a share subscription agreement with EPSO-G Invest UAB and to approve the material terms and conditions of such agreement. Pursuant to Article 41(xiii) of the Articles of Association of UAB EPSO-G, the resolution shall require the approval of the sole shareholder in order to become effective.

Agenda item of the meeting:

1. Regarding approval of the Resolution of the Board of UAB EPSO-G to increase the Share Capital of EPSO-G Invest UAB, to enter into a share subscription agreement with UAB EPSO-G Invest, and to Approve the material terms and conditions of such agreement.

Proposed resolution:

1. Regarding approval of the resolution of the Board of UAB EPSO-G to increase the share capital of UAB EPSO-G Invest, to enter into a share subscription agreement with UAB EPSO-G Invest, and to approve the material terms and conditions of such agreement.

1. 1. To approve the resolution of the Board of UAB EPSO-G dated 15 September 2026:
   2. To increase the share capital of UAB EPSO-G Invest by EUR 3,360,000, from EUR 7,405,600 to EUR 10,765,600, by issuing 3,360,000 ordinary registered shares of UAB EPSO-G Invest, each with a nominal value of EUR 1.
   3. To enter into a share subscription agreement with UAB EPSO-G Invest and to approve the material terms and conditions of such agreement:

Parties to the Agreement	The company whose shares are subscribed for – UAB EPSO-G Invest, legal entity code 306949519, registered office address Laisvės pr. 10, Vilnius, Lithuania (“EPSO-G Invest”, the “Company”); The subscriber of the shares – UAB EPSO-G, legal entity code 302826889, registered office address Laisvės pr. 10, LT-04215 Vilnius, Lithuania (“EPSO-G”, the “Subscriber”).
Object and subject matter of the Agreement	The Company undertakes to deliver to the Subscriber 1,713,600 newly issued shares of the Company, each with a nominal value of EUR 1 and an issue price of EUR 10 (the “Shares”), and the Subscriber undertakes to pay the issue price of the subscribed Shares (the “Issue Price”) in accordance with the procedure and within the time limits set out in this Agreement. Issue Price – EUR 17,136,000. Of this amount, EUR 1,713,600 shall be allocated to the increase of the Company’s share capital, and EUR 15,422,400 shall be transferred to share premium.
Procedure and terms for payment for the Shares	The Subscriber shall pay the Issue Price of EUR 17,136,000 for the 1,713,600 shares acquired by the Subscriber under the Agreement when the need arises to pay for the newly issued shares of Rheinmetall Defence Lietuva, UAB by additional monetary contributions of the Company due to the increase of the share capital of Rheinmetall Defence Lietuva, UAB, but in any event no later than 28 September 2026. Upon receipt of the relevant notice, EPSO-G shall use reasonable efforts to make the payment earlier.

The total issue price of the newly issued shares of EPSO-G Invest will amount to EUR 33,600,000, of which EUR 30,240,000 will be allocated to the share premium. EPSO-G will invest EUR 17,136,000 (51%), while Valstybės investicinis kapitalas will invest EUR 16,464,000 (49%).

The EPSO-G group of companies consists of the holding company EPSO-G and its six direct subsidiaries Amber Grid, Baltpool, Energy cells, EPSO-G Invest, Litgrid and Tetas. EPSO-G and its Group companies also hold shares in Rheinmetall Defence Lietuva, Baltic RCC OÜ and TSO Holding AS. The rights and obligations of the sole shareholder of EPSO-G are exercised by the Ministry of Energy of the Republic of Lithuania.

For more information, contact
Gediminas Petrauskas, communication partner of EPSO-G
Tel: +370 610 63306, email: gediminas.petrauskas@epsog.lt

Ticker symbol to remain “OBK”

RUSTON, La., Sept. 15, 2026 (GLOBE NEWSWIRE) — Origin Bancorp, Inc. (NYSE: OBK) (“Origin”), the holding company for Origin Bank, announced today that it will transfer its stock exchange listing from the New York Stock Exchange (“NYSE”) to the Texas Stock Exchange (“TXSE”). Origin expects to begin trading on the TXSE on October 13, 2026, and will continue to trade under its current ticker symbol “OBK”.

“Texas has played a central role in Origin’s growth story, and our decision to transfer trading to the Texas Stock Exchange reflects the long-term opportunity we see across the state’s diverse markets, including Dallas, Houston and East Texas,” said Drake Mills, chairman, president and CEO of Origin Bancorp, Inc. “As a company with deep roots in Louisiana and a growing presence across Texas and the broader region, this transition aligns our listing with one of the country’s most dynamic business centers and supports our continued focus on creating long-term value for stockholders.”

“Origin is a premier regional banking franchise with a strong history of serving customers across Louisiana, Texas and the broader Gulf South,” said James H. Lee, chairman and CEO of the Texas Stock Exchange. “As the only primary listings venue in the Boom Belt, the Texas Stock Exchange is proud to welcome Origin as one of our founding members, and we look forward to supporting its continued growth and value creation for stockholders.”

No action is required by stockholders with respect to the transfer of the listing. Origin’s common stock is expected to continue to be listed on the NYSE through market close on October 12, 2026.

About Origin Bancorp, Inc.

Origin Bancorp, Inc. is a financial holding company headquartered in Ruston, Louisiana. Origin’s wholly owned bank subsidiary, Origin Bank, was founded in 1912 in Choudrant, Louisiana. Deeply rooted in Origin’s history is a culture committed to providing personalized relationship banking to businesses, municipalities, and personal clients to enrich the lives of the people in the communities it serves. Origin provides a broad range of financial services and currently operates more than 57 locations in Dallas/Fort Worth, East Texas, Houston, North Louisiana, Mississippi, Alabama and the Florida Panhandle. In addition, Origin provides a broad range of insurance agency products and services through its wholly owned insurance agency subsidiary, Forth Insurance, LLC. For more information, visit www.origin.bank and www.forthinsurance.com.

Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of and pursuant to the Private Securities Litigation Reform Act of 1995 regarding, among other things, Origin transferring its listing to the TXSE and the expected benefits from and impact of the transfer of the listing. These statements are not historical in nature and may often be identified by the use of words such as “believes,” “projects,” “expects,” “may,” “estimates,” “should,” “plans,” “targets,” “intends” “could,” “would,” “anticipates,” “potential,” “confident,” “optimistic” or the negative thereof, or other variations thereon, or comparable terminology, or by discussions of strategy, objectives, estimates, trends, guidance, expectations and future plans.

Because forward-looking statements relate to future results and occurrences, they are subject to inherent and various uncertainties, risks, and changes in circumstances that are difficult to predict, may change over time, are based on management’s expectations and assumptions at the time the statements are made and are not guarantees of future results. Numerous risks and other factors, many of which are beyond management’s control, could cause actual results to differ materially from future results expressed or implied by such forward-looking statements. While there can be no assurance that any list of risks is complete, important risks and other factors that could cause actual results to differ materially from those contemplated by forward-looking statements include, but are not limited to, operational, regulatory or technical challenges related to the TXSE-listing; and the risks and factors more fully described in Origin’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other documents and filings with the SEC. The information contained in this communication speaks only as of its date. Except to the extent required by applicable law or regulation, we disclaim any obligation to update such factors or to publicly announce the results of any revisions to any of the forward-looking statements included herein to reflect future events or developments.

Contact Information
Investor Relations
Chris Reigelman
318-497-3177
chris@origin.bank

Media Contact
Ryan Kilpatrick
318-232-7472
rkilpatrick@origin.bank

FDA clearance of a new IND for GTB-5550 in multiple myeloma (MM) under an investigator sponsored trial (IST) protocol

Initiation of Phase 1 trial in MM patients contingent upon timing and receipt of non-dilutive grant funding

Phase 1 dose escalation basket trial with GTB-5550 in solid tumor patients continues to actively enroll, with an update anticipated in Q4 2026

Unaudited proforma cash balance as of September 15, 2026 of approximately $11 million anticipated to provide sufficient cash runway into Q3 2027

SAN FRANCISCO, CALIFORNIA, Sept. 15, 2026 (GLOBE NEWSWIRE) — GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary TriKE^® natural killer (NK) cell engager platform, today announced IND clearance from the FDA for GTB-5550 in multiple myeloma.

“Today’s IND to expand the potential indications for GTB-5550 highlights the diverse utility of our Trike^® platform,” said Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma. “The company remains focused on its two ongoing Phase 1 trials with GTB-5550 and GTB-3650, both of which are actively enrolling, and we look forward to the potential initiation of a third Phase 1 trial, pending receipt of non-dilutive grant funding.”

“Targeting B7-H3 remains an active area for clinical development of new anti-cancer drugs, yet most competitive efforts are focused on solid tumors”, said Dr. Aimee Merino, MD, PhD, Assistant Professor of Medicine, Division of Hematology, Oncology and Transplantation, The University of Minnesota¹. “Based on our findings of high levels of B7-H3 expression within the bone marrow of newly diagnosed multiple myeloma patients, we have begun a dedicated effort for this novel approach in later-line patients, which continues to be an area of unmet need. We have been encouraged with our preclinical findings in a bone chip model that show high levels of antitumor cell activity mediated by NK cells in the presence of GTB-5550.”

The Phase 1a/1b trial with GTB-5550 will be the first-in-human trial of a B7-H3-targeted TriKE^® in multiple myeloma and will use more patient-friendly subcutaneous administration intended to extend the half-life relative to prior intravenous TriKE formulations. The Phase 1a dose escalation portion will enroll 4^th line and later patients with multiple myeloma and evaluate up to 6 dose cohorts to identify the maximum tolerated dose (MTD). Following dose escalation, the Phase 1b expansion cohort will enroll a total of 25 patients treated at the MTD and further evaluate safety, tolerability, and preliminary anti-tumor activity.

In the Phase 1 trial, GTB-5550 will be administered by subcutaneous (SQ) injection in the abdominal area on 3 non-consecutive days per week during Week 1 and Week 2, followed by 2 weeks of no treatment. One treatment cycle is 4 weeks in duration, and this dosing schedule is repeated for each subsequent cycle. A minimum of 2 cycles is planned, and disease reassessment (monoclonal protein and free light chain analysis) is performed on Day 28 of each cycle. Patients with stable disease may continue for up to 4 cycles total, and those with a partial response or better may continue for up to 1 year. Patients are followed for 12 months from the first dose of GTB-5550 to determine progression-free survival (PFS) and overall survival (OS).

About GT Biopharma, Inc.

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE^® NK cell engager platform. Our TriKE^® platform is designed to harness and enhance the cancer killing abilities of a patient’s immune system’s natural killer cells. GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE^® technology. For more information, please visit gtbiopharma.com.

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” regarding future events and our future results. All statements other than statements of historical facts are statements that could be deemed to be forward-looking statements. These statements are based on current expectations, estimates, forecasts, and projections about the markets in which we operate and the beliefs and assumptions of our management. Words such as “expects,” “anticipates,” “targets,” “goals,” “projects”, “intends,” “plans,” “believes,” “seeks,” “estimates,” “endeavors,” “strives,” “may,” or variations of such words, and similar expressions are intended to identify such forward-looking statements. Readers are cautioned that these forward-looking statements are subject to a number of risks, uncertainties and assumptions that are difficult to predict, estimate or verify. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Such risks and uncertainties include those factors described in our most recent annual report on Form 10-K, as such may be amended or supplemented by subsequent quarterly reports on Form 10-Q, or other reports filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements are made only as of the date hereof, and we undertake no obligation to publicly release the result of any revisions to these forward-looking statements. For more information, please refer to our filings with the Securities and Exchange Commission.

TriKE^® is a registered trademark owned by GT Biopharma, Inc.

Investor Relations Contact:
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
212-915-2577

LinkedIn |Facebook |X |Instagram | YouTube

¹ The University of Minnesota, pursuant to its license agreement with GT Biopharma, is entitled to receive royalties should commercial sales of product using the TriKE technology be realized, including GTB-3650 and GTB-5550. This interest has been reviewed and managed by the University of Minnesota in accordance with its conflict of interest policies.

Tuesday, September 15, 2026

Dear Shareholders and Investors,

We are currently experiencing a market for our vessels that is extraordinary.

Below is a snapshot of some recent spot fixtures for our ships – the numbers are approximate.

Our operating costs per ship are less than $10,000 per day. The difference between the rates below and the operating costs is cash accumulation in NAT:

Fixture to Oil Major for a 31-day voyage, producing a rate of about $183,000 per day.

Fixture to Oil Trader for a 60-day voyage, giving a rate of about $200,000 per day.

Voyage to Oil Trader for a 80-day voyage. The rate is about $98,000 per day.

To Oil Major for a 65-day voyage. The Time Charter Equivalent (TCE) is about $70,000 per day. 

Spot fixture to Oil Major for a 19-day voyage. The TCE is about $88,000 per day.

To Oil Major for a 77-day voyage. The TCE is USD 61,000 per day.

Spot fixture to Oil trader for a 64-day voyage. The TCE is about $60,000 per day.

NAT vessel to Oil Major for a 53-day voyage. The TCE is about $60,000 per day.

By nature, spot contracts are volatile, which is why we see short term variations.

The direction is unquestionably upwards for NAT.

For further information on Nordic American Tankers. Please see our web page www.nat.bm 

Sincerely,

Herbjorn Hansson
Founder, Chairman & CEO
Nordic American Tankers Ltd.                                                        www.nat.bm

Contacts:       

Bjørn Giæver, CFO                                                             
Nordic American Tankers Ltd                                             
Tel: +1 888 755 8391                                  

Alexander Kihle, Finance Manager
Nordic American Tankers Ltd
Tel: +47 91 724 171    

 

TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) — McFarlane Lake Mining Limited (“McFarlane” or the “Company”) (CSE: MLM, OTC: MLMLF, FRA: W2Z) is pleased to announce that it will be featured in an upcoming segment produced by BTV – Business Television, airing on the BNN Bloomberg channel in Canada. The segment, titled “BTV Explores: What Investors Should Look for in Mining Companies,” includes commentary from strategic investor Michael Gentile on key factors investors should evaluate in mining companies, including grade, scale, infrastructure, and jurisdiction, and features McFarlane alongside several other companies in the sector.

The segment is scheduled to air on BNN Bloomberg on **Wednesday, September 16, 2026, at 7:30 p.m. ET**, with a repeat broadcast on **Saturday, September 19, 2026, at 8:00 p.m. ET**. It will also air on U.S. national television via the Biz Television Network on multiple dates between September 20 and September 25, 2026.

“We’re pleased to have McFarlane’s story featured as part of this segment, which highlights the strengthened financial position and growth potential of our Juby Gold Project to a broad investor audience,” said Mark Trevisiol, Chief Executive Officer, President and Director of McFarlane. “We look forward to continuing to build awareness of our story as we advance toward our next set of catalysts.”

Further Information

For further information regarding McFarlane, please contact:

Mark Trevisiol,
Chief Executive Officer, President and Director, McFarlane Lake Mining Limited
(705) 665-5087
mtrevisiol@mcfarlanelakemining.com  

Bryan Baritot, Investor Relations
McFarlane Lake Mining Limited
investors@mcfarlanelakemining.com

Expanded partnership with TradeCentric brings PunchOut, Purchase Order Automation, and Invoice Automation directly into customers’ existing eProcurement systems

• TradeCentric enables Xometry customers to streamline purchasing and invoicing (PunchOut, Purchase Order Automation, and Invoice Automation) directly within their existing eProcurement systems, reducing manual data entry and friction.
• The integration connects with 220+ eProcurement solutions, including Coupa, SAP Ariba, and Microsoft Dynamics, letting buyers source custom manufacturing directly through their eProcurement portal.
• According to TradeCentric data, companies that use PunchOut reduce time spent on purchase order management by 80%, freeing procurement teams to focus on higher-value work.

NORTH BETHESDA, Md., Sept. 15, 2026 (GLOBE NEWSWIRE) — Xometry, Inc. (NASDAQ: XMTR), the global AI-native marketplace connecting buyers and suppliers of custom manufacturing, announced an expanded partnership with TradeCentric, adding Purchase Order Automation and Invoice Automation to the PunchOut capability already available between Xometry’s marketplace and its customers’ eProcurement systems.

TradeCentric is a leading provider of B2B eProcurement integration solutions, connecting enterprise buyers and suppliers to efficiently and securely manage orders, catalogs, and transactions. Trusted by businesses worldwide, TradeCentric simplifies the way companies transact to streamline operations and increase profitability.

PunchOut, Purchase Order Automation, and Invoice Automation: Direct From Customers’ eProcurement Systems

With TradeCentric, Xometry customers can PunchOut directly into Xometry’s marketplace from their eProcurement systems to seamlessly configure parts and generate a quote, then send their cart back as a requisition for internal approval and purchase order creation. Now with the expanded partnership, Xometry customers also have purchase order and invoice automation options to receive electronic invoices, eliminate manual data entry, shorten the reconciliation timeline, minimize exceptions, and improve three-way matching. 

TradeCentric’s integration works with all major systems, including Coupa, SAP Ariba, and Microsoft Dynamics, as well as 220+ other eProcurement solutions, ensuring orders are securely transmitted, accurate, and easy to manage across enterprise environments.

“Establishing Xometry as the digital infrastructure for custom manufacturing means meeting our customers directly within the tools and enterprise workflows they rely on every day,” said Sanjeev Singh Sahni, CEO of Xometry. “Expanding our integrations with TradeCentric brings Xometry directly into our customers’ existing eProcurement systems to streamline purchasing, reduce operational friction, and accelerate product development at scale.”

“The seamless connection between Xometry and our procurement system has transformed how we manage our custom manufacturing orders. The ability to PunchOut to Xometry’s marketplace ensures that our team can source components instantly while staying fully compliant with our internal spend workflows. We’ve seen an increase in productivity now that our buyers can finalize complex orders quickly, ensuring our projects stay on schedule and under budget,” said Chet Bejtlich, Senior Consulting Engineer of Entegris.

“At TradeCentric, we’re focused on helping organizations accelerate results by making it easier to do business with their buyers,” said Elizabeth Segovia, CEO of TradeCentric. “Our collaboration with Xometry delivers intelligent eProcurement integration that empowers enterprise buyers and suppliers to connect, transact, and innovate faster. By eliminating integration complexity and operational friction, we’re creating new opportunities for suppliers to drive revenue growth and efficiency at scale across the manufacturing ecosystem.”

The integration is available now for Xometry customers in the U.S. and expanding to international markets. Learn more at Xometry.com or book a demo today.

About Xometry
Xometry’s (NASDAQ: XMTR) AI-native marketplace, popular Thomasnet^® industrial sourcing platform and suite of cloud-based services are rapidly digitizing the manufacturing industry. Xometry provides manufacturers the critical resources they need to grow their businesses and streamlines the procurement process for buyers through real-time pricing and lead time data. Learn more at xometry.com or follow Xometry on LinkedIn.

About TradeCentric
TradeCentric helps enterprise suppliers integrate commerce and accelerate results by making it easier to do business with their buyers. Our platform delivers intelligent eProcurement integrations that connect eCommerce and procurement systems through solutions like PunchOut, Purchase Order Automation, and Invoice Automation. Built with intention and designed to scale, TradeCentric eliminates integration complexity and operational friction, enabling suppliers to grow revenue, drive efficiency, and power results in a new era of B2B growth. Learn more at TradeCentric.com and follow on LinkedIn.

Media Contact
Lauran Cacciatori
VP Communications
773-610-0806
lauran.cacciatori@xometry.com

Investor Contact
Shawn Milne
VP Investor Relations
240-335-8132
shawn.milne@xometry.com